Overview

[11C]Carfentanil PET Study of GSK1521498

Status:
Completed
Trial end date:
2009-12-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether GSK1521498 attaches to sites in the brain called mu-opioid receptors that are involved in the liking reactions to palatable high fat and high sugar foods. We hope that blocking these receptors may modify certain behaviours that may lead to obesity.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Carfentanil
Fentanyl
Naltrexone